Download Freestyle Libre Data __EXCLUSIVE__
Bill Keplar
We use functional cookies to analyze your use of the site, improve performance and provide a better customer experience. We use advertising cookies to allow us, through certain data assigned and obtained from the user's device, to store or share with third parties information related to user's browsing activity in our website, in order to create an advertising profile and place relevant advertising in our website or those third parties websites. For more information about how Abbott uses cookies please see our Cookie Policy and Privacy Policy
هذا موقع خاص بالمنتج حصريًا للأشخاص المقيمين في لبنان. إذا كنت تعيش في بلد آخر فيرجى التواصل مع ممثل شركة أبوت المحلي لديك للحصول على معلومات المنتج الصحيحة لبلد إقامتك (انقر على "الانتقال إلى الموقع العالمي"). لزيارة الموقع المحلي باللغة العربية انقر على "البقاء هنا" أو قم بزيارة الصفحة المحلية باللغة الإنجليزية بالنقر على freestyle.abbott/lb-en
Whilst we know how every hour and every day is different, your AGP is a simple and easy way for you and your healthcare professional to visualise your changing glucose levels. It is created through the data you collect using your FreeStyle Libre 2 reader or FreeStyle LibreLinkØ app over several days or weeks (minimum of 5 days).
LibreView then aggregates your readings into a single 24-hour period, creating a view of a 'typical day'. Being able to see your data in this way allows you to identify times of day when your glucose levels fluctuate most from your target range.
With LibreView you can store all your FreeStyle Libre 2 sensor glucose data in one secure cloud-based solution. Each time you scan your FreeStyle Libre 2 sensor with the FreeStyle LibreLink appØ, your glucose data is automatically uploaded to LibreView.
Following an easy, one-off setup, your healthcare professional will be able to view your glucose data on LibreView. Plus, they can access insightful reports to help prepare for your in-person or telehealth appointments, helping you to get the most out of every consultation.
LibreView is a cloud-based diabetes management system provided by Abbott and Newyu, Inc. LibreView provides a secure repository for data from your FreeStyle LibreLink app, and allows you to easily share your glucose data with your healthcare professional or others, if you wish. Data is automatically8 uploaded to LibreView when your phone is connected to the Internet.
This website and the information contained herein is intended for outside of the US only.
For any product related information and further details on Abbott Products in Australia please visit www.myfreestyle.com.au. The FreeStyle Libre and FreeStyle Libre 2 Flash Glucose Monitoring System is indicated for measuring interstitial fluid glucose levels in people (aged 4 and older) with insulin-requiring diabetes. The indication for children (age 4 - 17) is limited to those who are supervised by a caregiver who is at least 18 years of age. Always read the label and use as directed.
Abbott Diabetes Care, 666 Doncaster Road, Doncaster VIC 3108 Australia. ABN 95 000 180 389. ADC-29573 V61.0
For more information call Customer Service on 1800 801 478.
Copyright 2023 Abbott. All Rights Reserved. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott.
The LibreLinkUp app is only compatible with certain mobile devices and operating systems. Please check www.librelinkup.com for more information about device compatibility before using the app. Use of LibreLinkUp requires registration with LibreView. The LibreLinkUp mobile app is not intended to be a primary glucose monitor: home users must consult their primary device(s) and consult a healthcare professional before making any medical interpretation and therapy adjustments from the information provided by the app.
The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice.
MADRID, Feb. 20, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that four real-world data abstractsi,ii,iii,iv are being presented during the 13th Advanced Technologies & Treatments for Diabetes (ATTD) in Madrid. The new data show that users of the FreeStyle Libre system have improved glucose control,iii increased time in target glucose range,iii and decreased time in hyperglycemiaiv (high glucose levels) and hypoglycemiaiv (low glucose levels), as well as reduced HbA1Ci,ii (average glucose levels over a three month period).ii
Enables electronic data upload from the FreeStyle Libre Family of Products. Include USB charging adapter to enable recharging of the FreeStyle Libre 2 and FreeStyle Libre 14 day systems. Using this data cable and any compatible health management system, you can upload your glucose results to create graphs and reports to support an effective diabetes management program.
FreeStyle Libre 14 day system: Failure to use FreeStyle Libre 14 day system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or www.freestylelibre.us for safety info.
FreeStyle Libre 2 system: Failure to use FreeStyle Libre 2 system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose alarms and readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or www.freestylelibre.us for safety info.
* Data from this study was collected with the outside US version of FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional, real-time glucose alarms. Therefore, the study data is applicable to both products.
** The LibreLinkUp app is only compatible with certain mobile device and operating systems. Please check www.librelinkup.com for more information about device compatibility before using the app. Use of the LibreLinkUp app requires registration with LibreView. LibreLinkUp is not intended to be used for dosing decisions. The user should follow instructions on the continuous glucose monitoring system. LibreLinkUp is not intended to replace self-monitoring practices as advised by a physician.
Click on "Create 1-Time Report" to begin upload. This option generates a viewable report for 24 hours in LibreView, does not require any patient information, and is not saved permanently.
Click on "Report Linked to Patient" to begin upload. This option adds the device data to the Patient Profile and is available for future viewing.
Note: You might receive different notifications when uploading a device, especially if it is the first time you are uploading said device. Please pay attention to the messaging and act accordingly.
When the upload is complete, you will land on the Glucose History section of the Patient Profile. By default, the All Data tab within the Glucose History will show all available data chronologically.
If your patient is using a compatible mobile app within the FreeStyle Libre portfolio, the data is automatically uploaded to LibreView every time there is an internet connection. If the patient is set up for remote sharing, the glucose data will automatically be available in their Patient Profile. Patients uploading via compatible mobile apps do not need to install any device drivers.
FreeStyle LibreLink may not be available everywhere LibreView is released.
CGM is widely used as the standard of care among patients with type 1 diabetes and is increasingly used among patients with type 2 diabetes as clinical trials and real-world data continue to show benefits of this technology for a broader range of people with diabetes.
De-identified data were obtained between 2014 and 2021 from patients using the system uninterrupted for a 24-week period. Glycemic parameters during first and last sensor use were examined in four identifiable groups: type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM) on basal-bolus insulin, T2DM on basal insulin, and T2DM without insulin treatment. Within each group, subgroup analyses were performed in persons with initial suboptimal glycemic regulation per the Time in Range consensus guidelines. Data were obtained from 1,909 persons with T1DM and 1,813 persons with T2DM (1,499 basal-bolus insulin, 189 basal insulin, and 125 non-insulin users). In most of the performed analyses, both overall and in the various subgroups, significant improvements were observed in virtually all predefined primary (TIR) and secondary endpoints (eHbA1c, TAR, TBR and glucose variability). 24-weeks of FreeStyle Libre use in real life by persons with T1DM and T2DM with suboptimal glycemic regulation is associated with improvement of glycemic parameters, irrespective of pre-use regulation or treatment modality.
df19127ead